Polpharma Biologics
About Polpharma Biologics
Certifications
-
FDA -
GMP
Categories
-
PL -
2021On CPHI since
-
2Certificates
-
1000 - 4999Employees
Company types
Primary activities
Products from Polpharma Biologics (2)
-
Product Biosimilar pipeline
https://polpharmabiologics.com/en/pipeline-portfolio/biosimilar-pipeline -
Product Pipeline
Polpharma Biologics has its own pipeline of biosimilars for out-licensing. We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.
Polpharma Biologics Resources (2)
-
News Polpharma Biologics announces FDA approval of Tyruko®
Polpharma Biologics, announced that the FDA is the first regulatory body worldwide to approve the use of Tyruko® (natalizumab-sztn) - a new biosimilar for the treatment of relapsing forms of multiple sclerosis (MS). Approval of Tyruko® by the European Medicines Agency is also expected imminently.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance